Chapter 22: Genetic Engineering & Biotechnology

Biotechnology utilizes living systems to produce beneficial products and processes, drawing heavily on genetic engineering and genomics. A crucial application is biopharming, the creation of biopharmaceutical products like therapeutic proteins to treat diseases. The production of Humulin (recombinant human insulin) marked the beginning of this era, initially using bacteria, but subsequent therapeutic proteins, such as antithrombin from transgenic goats or sebelipase alfa from transgenic chickens, utilize eukaryotic bioreactors to ensure necessary post-translational modifications like proper protein folding and glycosylation. Recombinant DNA also facilitates vaccine development, resulting in subunit vaccines against diseases like Hepatitis B and HPV (Gardasil), and exploring DNA-based vaccines for viruses such as Zika. In agriculture, genetic engineering focuses on developing GM crops with enhanced resistance to pests and herbicides, improved nutritional value, and future applications in sustainable biofuel production. Genetic technologies are foundational for medical diagnostics, including noninvasive prenatal screening that analyzes cell-free fetal DNA (cfDNA) circulating in maternal blood to detect conditions like Down syndrome. Techniques such as Allele-Specific Oligonucleotides (ASOs), which detect single-nucleotide changes (SNPs), are used for diagnosing single-gene disorders like sickle-cell anemia, and are frequently employed in Preimplantation Genetic Diagnosis (PGD) of IVF embryos. High-throughput methods, previously dominated by gene-expression microarrays for profiling messenger RNA changes in disease states like cancer, are being superseded by advanced genomic sequencing techniques. Whole-Genome Sequencing (WGS), Whole-Exome Sequencing (WES), and Single-Cell Sequencing (SCS) are accelerating the identification of mutations in both common and rare diseases. Population-level studies, specifically Genome-Wide Association Studies (GWAS), utilize genomic variations (SNPs, CNVs) to assess disease risk, often illustrating results on a Manhattan plot. Furthermore, the chapter introduces synthetic biology, which aims to engineer designer organisms; key achievements include defining the minimal bacterial genome (JCVI-syn3.0 with 473 essential genes) and engineering sophisticated DNA circuits that function as cellular memory devices. Finally, the vast implications of these advancements necessitate addressing critical Ethical, Legal, and Social Issues (ELSI), including protecting genetic privacy, regulating Direct-to-Consumer (DTC) tests, mitigating genetic discrimination (GINA Act), debating gene patenting (highlighted by the BRCA1/2 ruling), and evaluating the risks of gene drive technology for population control, such as in Aedes aegypti mosquitoes.